[
    [
        {
            "time": "2023-05-20",
            "original_text": "贝达药业CTLA-4抗体联合PD-1抗体治疗晚期宫颈癌药品临床试验申请受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "CTLA-4抗体",
                    "PD-1抗体",
                    "晚期宫颈癌",
                    "临床试验",
                    "受理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业CTLA-4抗体联合PD-1抗体治疗晚期宫颈癌药品临床试验申请受理",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-05-20",
            "original_text": "贝达药业公告，泽弗利单抗注射液联合巴替利单抗注射液治疗晚期宫颈癌的药品临床试验申请获得受理。",
            "features": {
                "keywords": [
                    "贝达药业",
                    "泽弗利单抗",
                    "巴替利单抗",
                    "晚期宫颈癌",
                    "临床试验",
                    "受理"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业公告，泽弗利单抗注射液联合巴替利单抗注射液治疗晚期宫颈癌的药品临床试验申请获得受理。",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 10
            }
        },
        {
            "time": "2023-05-20",
            "original_text": "风险众多，益方生物能够IPO成功？",
            "features": {
                "keywords": [
                    "益方生物",
                    "IPO",
                    "风险"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "风险众多，益方生物能够IPO成功？",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]